Approximately 14% of GIST cases develop secondary resistance, and, in this study, the immune checkpoint inhibitors developed mainly include programmed cell death-1/programmed cell death ligand-1, (PD1/PD-L1) and cytotoxic T-lymphocyte-associated protein-4 (CTLA4) [18]. Here, CTLA4 is linked to gastrointestinal stromal tumor.